{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:49Z","timestamp":1789972129514,"version":"4.0.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","oralmaxsurgery.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.coms.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T15:08:34Z","timestamp":1443366514000},"page":"489-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Pathophysiology of Osteonecrosis of the Jaws"],"prefix":"10.1016","volume":"27","author":[{"given":"Tara","family":"Aghaloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renna","family":"Hazboun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tetradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coms.2015.06.001_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib2","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.surge.2011.09.002","article-title":"Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review","volume":"10","author":"McLeod","year":"2012","journal-title":"Surgeon"},{"key":"10.1016\/j.coms.2015.06.001_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijom.2009.11.014","article-title":"Surgical management of bisphosphonate induced osteonecrosis of the jaws","volume":"39","author":"Williamson","year":"2010","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","article-title":"Bisphosphonates cause osteonecrosis of the jaw-like disease in mice","volume":"177","author":"Bi","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coms.2015.06.001_bib7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"12","key":"10.1016\/j.coms.2015.06.001_bib9","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.joms.2013.05.014","article-title":"Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications","volume":"71","author":"Carlson","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/SCS.0000000000000833","article-title":"Microsurgical reconstruction after bisphosphonate-related osteonecrosis of the jaw: our experience with fibula free flap","volume":"25","author":"Spinelli","year":"2014","journal-title":"J\u00a0Craniofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14737140.7.2.221","article-title":"Key roles of the OPG-RANK-RANKL system in bone oncology","volume":"7","author":"Baud'huin","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.coms.2015.06.001_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coms.2015.06.001_bib15","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2015.06.001_bib17","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1566524023362104","article-title":"Bisphosphonate mechanism of action","volume":"2","author":"Rodan","year":"2002","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.coms.2015.06.001_bib21","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1359\/jbmr.080516","article-title":"Review of nonprimate, large animal models for osteoporosis research","volume":"23","author":"Reinwald","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ar.a.20396","article-title":"Remodeling dynamics in the alveolar process in skeletally mature dogs","volume":"288","author":"Huja","year":"2006","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"10.1016\/j.coms.2015.06.001_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bjoms.2014.01.021","article-title":"Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates","volume":"52","author":"Ristow","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib25","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.joms.2014.07.004","article-title":"Bisphosphonate uptake in areas of tooth extraction or periapical disease","volume":"72","author":"Cheong","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","article-title":"Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates","volume":"86","author":"Kimmel","year":"2007","journal-title":"J\u00a0Dent Res"},{"key":"10.1016\/j.coms.2015.06.001_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.coms.2015.06.001_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1254\/jphs.FMJ05004X2","article-title":"Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts","volume":"100","author":"Suzuki","year":"2006","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.coms.2015.06.001_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(99)00197-0","article-title":"Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment","volume":"25","author":"Ito","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.coms.2015.06.001_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coms.2015.06.001_bib31","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib32","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00520-012-1461-4","article-title":"Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients","volume":"20","author":"Dranitsaris","year":"2012","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.coms.2015.06.001_bib33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jbmr.2097","article-title":"RANK-L inhibitors induce osteonecrosis of the jaw in mice with periapical disease","volume":"29","author":"Aghaloo","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib34","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/jbmr.1894","article-title":"Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice","volume":"28","author":"Kang","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib35","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.ajpath.2014.07.010","article-title":"Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice","volume":"184","author":"Williams","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coms.2015.06.001_bib36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.coms.2015.06.001_bib37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coms.2015.06.001_bib38","first-page":"33","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays","volume":"61","author":"Damm","year":"2013","journal-title":"Gen Dent"},{"key":"10.1016\/j.coms.2015.06.001_bib39","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of\u00a0denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3\u00a0pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.coms.2015.06.001_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12020-012-9696-x","article-title":"Skeletal and extraskeletal actions of denosumab","volume":"42","author":"Sinningen","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.coms.2015.06.001_bib41","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2015.06.001_bib42","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coms.2015.06.001_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02405012","article-title":"Structure-activity relationships of various bisphosphonates","volume":"35","author":"Shinoda","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.coms.2015.06.001_bib44","first-page":"645","article-title":"Denosumab: an investigational drug for the management of postmenopausal osteoporosis","volume":"2","author":"Lewiecki","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.coms.2015.06.001_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/BOR.0b013e32832ca41c","article-title":"Denosumab update","volume":"21","author":"Lewiecki","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coms.2015.06.001_bib46","first-page":"302","article-title":"Denosumab: recent update in postmenopausal osteoporosis","volume":"37","author":"Silva","year":"2012","journal-title":"Acta Reumatol Port"},{"issue":"9","key":"10.1016\/j.coms.2015.06.001_bib47","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.2490","article-title":"OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice","volume":"30","author":"de Molon","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0022034513487558","article-title":"Intra-oral PTH administration promotes tooth extraction socket healing","volume":"92","author":"Kuroshima","year":"2013","journal-title":"J\u00a0Dent Res"},{"key":"10.1016\/j.coms.2015.06.001_bib49","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-013-2570-8","article-title":"Early effects of parathyroid hormone on bisphosphonate\/steroid-associated compromised osseous wound healing","volume":"25","author":"Kuroshima","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.coms.2015.06.001_bib50","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.ijom.2013.05.001","article-title":"The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study","volume":"42","author":"Dayisoylu","year":"2013","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1010063225902","article-title":"Regulation of osteoclast formation and function","volume":"2","author":"Duong","year":"2001","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.coms.2015.06.001_bib52","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib53","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib54","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib55","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2006.02.011","article-title":"Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?","volume":"64","author":"Zavras","year":"2006","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib56","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A\u00a0retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib57","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-160X-6-11","article-title":"Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients","volume":"6","author":"Walter","year":"2010","journal-title":"Head Face Med"},{"key":"10.1016\/j.coms.2015.06.001_bib59","series-title":"Oral and intravenous bisphosphonate induced osteonecrosis of the jaws: history, etiology, prevention, and treatment","author":"Marx","year":"2007"},{"key":"10.1016\/j.coms.2015.06.001_bib60","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib61","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0765.1981.tb00995.x","article-title":"The progress of the periodontal syndrome in the rice cat. II. The effects of a diphosphonate on the periodontium","volume":"16","author":"Gotcher","year":"1981","journal-title":"J\u00a0Periodontal Res"},{"key":"10.1016\/j.coms.2015.06.001_bib63","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.joms.2011.02.059","article-title":"Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws","volume":"69","author":"Lopez-Jornet","year":"2011","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib64","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.joms.2008.09.031","article-title":"Sinus tracts\u2013an early sign of bisphosphonate-associated osteonecrosis of the jaws?","volume":"67","author":"Mawardi","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2014.07.027","article-title":"Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model","volume":"68","author":"de Molon","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.coms.2015.06.001_bib66","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J\u00a0Clin Periodontol"},{"key":"10.1016\/j.coms.2015.06.001_bib67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J\u00a0Oral Pathol Med"},{"key":"10.1016\/j.coms.2015.06.001_bib70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.joms.2007.11.035","article-title":"Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy","volume":"66","author":"Sedghizadeh","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11914-010-0008-1","article-title":"The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy","volume":"8","author":"Kumar","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.coms.2015.06.001_bib72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ijos.2014.46","article-title":"Oral microbiota and host innate immune response in\u00a0bisphosphonate-related osteonecrosis of the jaw","volume":"6","author":"Pushalkar","year":"2014","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.coms.2015.06.001_bib73","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","article-title":"Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.coms.2015.06.001_bib74","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.joms.2012.12.005","article-title":"Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw?","volume":"71","author":"Kos","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.oooo.2012.08.446","article-title":"Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms","volume":"115","author":"Wanger","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.coms.2015.06.001_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.5435\/JAAOS-22-07-455","article-title":"Osteonecrosis of the femoral head: evaluation and treatment","volume":"22","author":"Zalavras","year":"2014","journal-title":"J\u00a0Am Acad Orthop Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib77","first-page":"1846","article-title":"Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy","volume":"161","author":"Gacche","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coms.2015.06.001_bib78","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.coms.2015.06.001_bib79","doi-asserted-by":"crossref","first-page":"43603","DOI":"10.1074\/jbc.M308114200","article-title":"Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B\/Akt","volume":"278","author":"Bezzi","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coms.2015.06.001_bib80","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coms.2015.06.001_bib81","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00784-013-1060-x","article-title":"Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in\u00a0vivo 3D Matrigel assay","volume":"18","author":"Pabst","year":"2014","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.coms.2015.06.001_bib82","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.coms.2015.06.001_bib83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib84","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Santos-Silva","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.coms.2015.06.001_bib85","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","article-title":"Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?","volume":"17","author":"Van den Wyngaert","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib86","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.coms.2015.06.001_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.coms.2015.06.001_bib88","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.coms.2015.06.001_bib89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.coms.2015.06.001_bib90","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coms.2015.06.001_bib91","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","article-title":"Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer","volume":"46","author":"Montague","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.coms.2015.06.001_bib92","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","article-title":"Inhibition of oral mucosal cell wound healing by bisphosphonates","volume":"66","author":"Landesberg","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2015.06.001_bib93","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3892\/ijmm.2014.1802","article-title":"Development of oral osteomucosal tissue constructs in\u00a0vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue","volume":"34","author":"Bae","year":"2014","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.coms.2015.06.001_bib94","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coms.2015.06.001_bib95","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/1471-2407-14-338","article-title":"Immunotherapy of hepatocellular carcinoma with small double-stranded RNA","volume":"14","author":"Kabilova","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.coms.2015.06.001_bib96","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.coms.2015.06.001_bib97","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.4317\/medoral.17150","article-title":"Extraction socket healing in rats treated with bisphosphonate: animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients","volume":"16","author":"Ali-Erdem","year":"2011","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.coms.2015.06.001_bib98","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series","volume":"123","author":"Fedele","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.coms.2015.06.001_bib99","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1601-0825.2012.01911.x","article-title":"Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines","volume":"18","author":"Patel","year":"2012","journal-title":"Oral Dis"}],"container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369915000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369915000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T21:24:15Z","timestamp":1567200255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042369915000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1042369915000497"],"URL":"https:\/\/doi.org\/10.1016\/j.coms.2015.06.001","relation":{},"ISSN":["1042-3699"],"issn-type":[{"value":"1042-3699","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology of Osteonecrosis of the Jaws","name":"articletitle","label":"Article Title"},{"value":"Oral and Maxillofacial Surgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coms.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}